英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03696 英矽智能

未开盘 08-13 16:08:14

46.380

+0.380

+0.83%

最高49.000	最低45.220	成交量1,407万
今开46.740	昨收46.000	日振幅8.22%
总市值269.93亿	流通市值269.93亿	总股本5.82亿
成交额6.63亿	换手率2.42%	流通股本5.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03696","market":"HK","secType":"STK","nameCN":"英矽智能","latestPrice":46.38,"timestamp":1786608494007,"preClose":46,"halted":0,"volume":14065119,"delay":0,"changeRate":0.008260869565217446,"floatShares":582000000,"shares":582000000,"eps":-4.48,"marketStatus":"未开盘","change":0.38,"latestTime":"08-13 16:08:14","open":46.74,"high":49,"low":45.22,"amount":663114386,"amplitude":0.082174,"askPrice":46.4,"askSize":500,"bidPrice":46.38,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-4.707,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":0,"adr":0,"listingDate":1767024000000,"exchange":"SEHK","adjPreClose":46,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":0.852132,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03696","defaultTab":"news","newsList":[{"id":"1142047299","title":"异动解读｜英矽智能盘中上涨5.09%，宣布与韩国THPharm达成研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1142047299","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142047299?lang=zh_cn&edition=full","pubTime":"2026-08-13 13:00","pubTimestamp":1786597244,"startTime":"0","endTime":"0","summary":"8月13日，英矽智能盘中上涨5.09%，报48.36港元，成交额3.16亿港元。消息面上，公司宣布与韩国THPharm达成研究合作，为近期密集落地的商业化合作再添一笔。此外，摩根大通于8月7日以均价43.61港元增持公司183.05万股，好仓比例升至5.1%；国泰海通证券首予公司\"增持\"评级，目标价73.23港元。公司还将于8月26日召开董事会审议中期业绩。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659762187","title":"港股异动 | 英硅智能(03696)盘中涨超4% 宣布与韩国THPharm达成研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2659762187","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659762187?lang=zh_cn&edition=full","pubTime":"2026-08-13 11:21","pubTimestamp":1786591269,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英硅智能盘中涨超4%，截至发稿，涨3%，报47.38港元，成交额2.59亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03696","BK4585","KCAI","BK4588","VXUS","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129477514","title":"英矽智能：摩根大通同日披露权益变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1129477514","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129477514?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:14","pubTimestamp":1786526058,"startTime":"0","endTime":"0","summary":"摩根大通于2026年8月7日以每股均价43.6099港元买入英矽智能股份183.05万股，涉资约7982.79万港元。同日，摩根大通增加淡仓，淡仓持股量由1229.74万股增至1400.54万股，占比由2.12%升至2.4%。摩根大通此次增持前持有英矽智能好仓2787.76万股，占比4.81%；增持后持股量为2970.81万股，好仓比例升至5.1%。淡仓方面，增加前持有1229.74万股（占比2.12%），增加后持有1400.54万股（占比2.4%）。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999682","title":"英硅智能(03696.HK)拟8月26日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999682","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658999682?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:47","pubTimestamp":1786441622,"startTime":"0","endTime":"0","summary":"格隆汇8月11日丨英硅智能(03696.HK)发布公告，谨定于2026年8月26日(星期三)举行董事会会议，以考虑及通过集团截至2026年6月30日止的六个月中期业绩，及考虑派发中期股息(如有)，以及处理其他事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260811/32331796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141355788","title":"英矽智能（03696）拟于8月26日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1141355788","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141355788?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:41","pubTimestamp":1786441280,"startTime":"0","endTime":"0","summary":"英矽智能8月11日发布公告称，公司董事会已决定于2026年8月26日（星期三）召开会议，议程包括：。独立非执行董事：王劲松博士、Denitsa Milanova博士、Roman Kyrychynskyi先生。公司董事会主席、执行董事、首席执行官及首席商务官Aleksandrs Zavoronkovs博士于2026年8月11日在香港签署本公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658160905","title":"国泰海通证券：首予英硅智能(03696)“增持”评级 目标价73.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658160905","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658160905?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:03","pubTimestamp":1786327435,"startTime":"0","endTime":"0","summary":"参考可比公司，该行给予公司2026年P/S 29倍，目标价为73.23港元，给予\"增持\"评级。国泰海通证券主要观点如下：全球领先的AI制药先行者，端到端全流程覆盖英硅智能是全球领先的AI制药先行者，利用其自主研发的生成式人工智能平台Pharma.AI实现端到端的药物研发全流程赋能。AI技术深度融合提升早期研发效率，临床阶段获实效验证AI技术的深度融合显著提升了早期研发效率，并开始在临床阶段获得实效验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","02611","EWH","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658097936","title":"AI医疗概念股普升 剂泰科技-P（07666）涨12.86%、晶泰控股（02228）涨10.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658097936","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658097936?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:03","pubTimestamp":1786327392,"startTime":"0","endTime":"0","summary":"金吾财讯 | AI医疗概念股盘初普升，截至发稿，剂泰科技-P 涨12.86%，晶泰控股涨10.26%，英硅智能涨9.38%，百奥赛图-B涨8.33%，讯飞医疗科技涨4.98%，医渡科技涨4.00%，云知声涨3.96%，平安好医生涨3.58%，阿里健康涨3.21%，京东健康涨2.98%。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/NDQ1MWJhN2NhODAzMzgwYTAyY2UxMDMzODA5NjE3NDc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NDQ1MWJhN2NhODAzMzgwYTAyY2UxMDMzODA5NjE3NDc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987779","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00241","07666","BK1583","BK1591","QTOC","09678","01833","BK1571","HK0000165453.HKD","03696","02506","SGXZ86797644.SGD","SGXZ62798434.SGD","06618","AGIX","VTHR","BK1518","BK1142","BK1141","BK1515","02158","BK1615","BK1161","AIPO","CHAT","BK1589","159891","BK1189","BK1219","BK1109","02315","86618","BK1617","02228","BK1584","LU0456827905.SGD","BK1501","BK1610","LU0051755006.USD","BK1247","ARTY","BK1502"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658360953","title":"港股异动 | 英硅智能(03696.HK)盘中涨超11% AI制药进入需求验证期 公司端到端全流程覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2658360953","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658360953?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:37","pubTimestamp":1786325874,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01477","BK1141","BK1574","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110483228","title":"异动解读｜英矽智能盘中上涨9.6%，NLRP3抑制剂获批临床叠加摩根大通首次覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1110483228","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110483228?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:30","pubTimestamp":1786325448,"startTime":"0","endTime":"0","summary":"8月10日，英矽智能盘中上涨9.6%，报49.76港元，成交额3348.81万港元。消息面上，公司与衡泰生物共同开发的血脑屏障穿透性NLRP3抑制剂ISM8969/HT-001近日获得NMPA新药临床试验批准，拟用于帕金森病治疗。该药物能穿透血脑屏障进入中枢神经系统，区别于其他外周限制性NLRP3抑制剂，具备神经炎症相关疾病的治疗潜力。此外，摩根大通首次覆盖公司并予\"增持\"评级及71港元目标价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657691079","title":"港股异动 | 英硅智能(03696)涨超9% ISM8969/HT-001已获NMPA临床试验批件 拟用于帕金森病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691079","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657691079?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:04","pubTimestamp":1786082650,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英硅智能涨超9%，截至发稿，涨8.1%，报44.3港元，成交额5.41亿港元。消息面上，近日，据英硅智能官微消息，英硅智能宣布，公司与衡泰生物共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局临床试验批件，拟用于帕金森病治疗。此前，英硅智能于2026年1月宣布与复星健康资本旗下深圳鹏复基金与复星医药的被投企业衡泰生物达成独家授权与合作协议，共同推进ISM8969/HT-001的全球开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1612","IBBJ","MDTX","PSYK","BK4181","HT","IBRN","03696","VXUS","BK4585","KCAI","BK1141","BK4218","01611","BK4588","BK1167","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146589195","title":"异动解读｜英矽智能盘中上涨5.61%，生命科学板块集体走强带动","url":"https://stock-news.laohu8.com/highlight/detail?id=1146589195","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146589195?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:03","pubTimestamp":1786079034,"startTime":"0","endTime":"0","summary":"8月7日，英矽智能盘中上涨5.61%，报43.28港元，成交额3.16亿港元。公司所在的生命科学工具和服务板块集体走强，药明合联涨9.75%、康龙化成涨9.14%、药明生物涨6.77%、药明康德涨5.56%，板块联动效应显著。公司层面，近期利好密集：与衡泰生物合作的NLRP3抑制剂ISM8969/HT-001获NMPA临床试验批准用于帕金森病治疗；摩根大通首次覆盖予\"增持\"评级及71港元目标价，叠加板块共振为股价提供支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英矽智能盘中上涨5.61%，生命科学板块集体走强带动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129389192","title":"英矽智能更新2026年7月股份变动月报表，股本增至582,436,846股","url":"https://stock-news.laohu8.com/highlight/detail?id=1129389192","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129389192?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:16","pubTimestamp":1786007800,"startTime":"0","endTime":"0","summary":"英矽智能于2026年8月6日公布截至2026年7月31日的股份变动月报表。报告显示，公司注册股本维持在1,270,000,000股普通股不变，面值为每股0.0000005美元，总注册股本为635美元。本期公司已发行股份由2026年6月底的575,837,982股增至582,436,846股，较上期增加6,598,864股。公司确认已持续符合香港联交所要求的公众持股量标准，最低公众持股量比例为已发行股份总数的15%。截至2026年7月底，公司总股本增至582,436,846股，库藏股保持为零。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123023734","title":"异动解读｜英矽智能盘中下跌5.78%，报43.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123023734","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123023734?lang=zh_cn&edition=full","pubTime":"2026-08-03 13:25","pubTimestamp":1785734738,"startTime":"0","endTime":"0","summary":"8月3日，英矽智能盘中下跌5.78%，报43.06港元/股，成交额5.1亿港元。英矽智能所在的生命科学工具和服务行业中，个股中，金斯瑞生物科技跌8.53%，药明康德跌0.12%，药明生物跌1.03%，药明合联跌1.16%，晶泰控股跌1.46%。英矽智能是一家主要从事人工智能驱动的药物发现及管线开发业务的公司。该公司通过自主开发的人工智能平台Pharma.AI产生了多项临床或新药临床试验申请阶段的资产，同时涉足软体解决方案和其他与非制药领域相关的研发业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英矽智能盘中下跌5.78%，报43.06港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656534982","title":"英硅智能(03696)与衡泰生物共同开发的血脑屏障穿透性 NLRP3 抑制剂 ISM8969/HT-001 获得 NMPA 新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656534982","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656534982?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:25","pubTimestamp":1785716738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，本公司与深圳衡泰生物科技有限公司共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局新药临床试验批准，用于治疗帕金森病。与其他临床进展较快但具外周限制性的NLRP3抑制剂相比，ISM8969/HT-001能够穿透血脑屏障并进入中枢神经系统，因此有望用于治疗与神经炎症相关的疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BMED","03696","BK1612","MDTX","PSYK","BK1167","IBBJ","IBBQ","BK4181","BK4218","HT","01611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100098819","title":"英矽智能与衡泰生物合作研发血脑屏障穿透性NLRP3抑制剂ISM8969/HT-001获NMPA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1100098819","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100098819?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:21","pubTimestamp":1785716477,"startTime":"0","endTime":"0","summary":"2026年8月3日，英矽智能发布自愿公告称，公司与深圳衡泰生物科技有限公司共同开发的口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局新药临床试验批准，用于治疗帕金森病。根据公告，本次临床试验将评估ISM8969/HT-001在健康受试者中的安全性、耐受性、药代动力学和药效动力学特征，并探索其在帕金森病患者中的初步疗效。官方信息显示，ISM8969/HT-001具备血脑屏障穿透能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655332153","title":"港股异动 | 英硅智能(03696.HK)涨超8% 发布业界首个“药物研发基准评估”","url":"https://stock-news.laohu8.com/highlight/detail?id=2655332153","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655332153?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:13","pubTimestamp":1785464013,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147410202","title":"异动解读｜英矽智能盘中上涨5.09%，ISM6331获FDA快速通道资格叠加行业回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=1147410202","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147410202?lang=zh_cn&edition=full","pubTime":"2026-07-31 09:32","pubTimestamp":1785461567,"startTime":"0","endTime":"0","summary":"7月31日，英矽智能盘中上涨5.09%，报44.64港元/股，成交额3074.28万港元。此前该股连续三个交易日累计回调约9%，今日迎来技术性反弹。消息面上，公司近日接连释放多项管线进展利好。7月29日，公司AI驱动的创新泛TEAD抑制剂ISM6331获美国FDA快速通道资格，用于治疗不可切除恶性胸膜间皮瘤；同时，ISM6331的I期临床数据已被ESMO 2026年会接收，将以口头报告形式发布。此外，公司核心管线Rentosertib已于7月8日正式启动III期临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英矽智能盘中上涨5.09%，ISM6331获FDA快速通道资格叠加行业回暖","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143799910","title":"异动解读｜英矽智能盘中下跌5.52%，报41.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143799910","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143799910?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:21","pubTimestamp":1785381716,"startTime":"0","endTime":"0","summary":"7月30日，英矽智能盘中下跌5.52%，报41.1港元/股，成交额2.14亿港元。英矽智能所在的生命科学工具和服务行业中，个股中，药明生物跌5.84%，金斯瑞生物科技跌4.83%，药明康德跌4.04%，晶泰控股跌3.53%，药明合联跌6.53%。英矽智能是一家主要从事人工智能驱动的药物发现及管线开发业务的公司。该公司通过自主开发的人工智能平台Pharma.AI产生了多项临床或新药临床试验申请阶段的资产，同时涉足软体解决方案和其他与非制药领域相关的研发业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113277926","title":"异动解读｜英矽智能盘中下跌5.31%，报40.62港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113277926","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113277926?lang=zh_cn&edition=full","pubTime":"2026-07-29 10:19","pubTimestamp":1785291585,"startTime":"0","endTime":"0","summary":"7月29日，英矽智能盘中下跌5.31%，报40.62港元/股，成交额1.74亿港元。英矽智能所在的生命科学工具和服务行业中，个股中，药明生物涨0.88%，药明康德涨0.13%，药明合联涨0.28%，金斯瑞生物科技跌0.3%，晶泰控股跌4.21%。英矽智能是一家主要从事人工智能驱动的药物发现及管线开发业务的公司。该公司通过自主开发的人工智能平台Pharma.AI产生了多项临床或新药临床试验申请阶段的资产，同时涉足软体解决方案和其他与非制药领域相关的研发业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171028235","title":"英矽智能（03696）AI 研发新药 ISM6331 获美国 FDA 快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1171028235","media":"公告速递","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171028235?lang=zh_cn&edition=full","pubTime":"2026-07-29 08:21","pubTimestamp":1785284476,"startTime":"0","endTime":"0","summary":"2026年7月29日，英矽智能公告，其自研 AI 驱动的创新泛 TEAD 抑制剂 ISM6331 已获美国食品药品监督管理局授予快速通道资格，用于治疗既往接受过抗 PD-1 抗体治疗及含铂化疗后疾病进展、不可切除恶性胸膜间皮瘤的成年患者。根据 FDA 政策，快速通道旨在加速针对严重或危及生命疾病且存在未满足医疗需求的新药的开发与审评。时间节点方面，ISM6331 于2024年获 FDA 授予孤儿药资格认定；2025年1月完成全球多中心 I 期临床试验首例患者给药；2026年7月再获 FDA 快速通道资格。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://insilico.com","stockEarnings":[{"period":"1week","weight":0.1063},{"period":"1month","weight":0.0236},{"period":"3month","weight":-0.2103},{"period":"6month","weight":-0.3741},{"period":"1year","weight":0.9127},{"period":"ytd","weight":0.2386}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"英矽智能是一家主要从事人工智能驱动的药物发现及管线开发业务的公司。该公司主要业务包括自主开发候选药物，共同开发，授权药物并保留部分知识产权及与其他制药公司合作但不保留任何知识产权。该公司通过自主开发的人工智能平台 Pharma.AI产生了多项临床或新药临床试验申请阶段的资产。此外，该公司也涉足软体解决方案和其他与非制药领域相关的研发业务。","exchange":"SEHK","name":"英矽智能","nameEN":"INSILICO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英矽智能,03696,英矽智能股票,英矽智能股票老虎,英矽智能股票老虎国际,英矽智能行情,英矽智能股票行情,英矽智能股价,英矽智能股市,英矽智能股票价格,英矽智能股票交易,英矽智能股票购买,英矽智能股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}